Use PowerPatent’s Online Patent Filing Service to get quick patent protection for your great idea.
The Janssen Pharmaceutica Nv patent solves the following problem:
Flap is a key initiator of the summary way leukotriene that bind and then move arachidonic acid into the 5-lipoxygenase (M. Abramovitz et al., 5-lipoxygenase-activating protein stimulates the use of arachidonic acid by 5 -lipoxygenase, Eur. J. Biochem., 1993, 215, 105-11). Flap shown to interact with the LTC4 synthase, and putatively modulate the production of LTC4 (T. Strid et al., Different parts of leukotriene C (4) synthase interact with the 5-lipoxygenase and 5-lipoxygenase activating protein, Biochem. Biophys. Res. Comm., 2009, 381 (4), 518-22). . Modulation (including without limitation restrictions) or the gene deletion flap block leukotriene production, particularly LTB4, cysteinyl leukotrienes (LTC4, LTD4 and LTE4) as well as 5-oxo-food (JZ Haeggstrm et al, lipoxygenase and leukotriene pathway : biochemistry, biology, and role in disease, Chem Rev., 2011, 111 (10), 5866-98).
Our analysis of this patent is as follows:
Janssen Pharmaceutica Nv’s patent US 9089569 B2 deals with 1,2,6-substituted benzimidazoles as flap modulators.
The present invention relates to compounds of Formula (I), and solvates, Refreshing, and pharmaceutically acceptable salts thereof, wherein X1, X1, X1, R1, R2 and P3 as described here, useful as modulators flap . The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) within the scope of the invention.
The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.